Table 5.
A comparison of HTA and MCDA outcomes (economic criteria excluded) for 50 % threshold, multiple HTA restrictions imposed
| HTA | |||||||
|---|---|---|---|---|---|---|---|
| Positive | Negative | ||||||
| Unrestricted | Time restrictions | Limits to specific subpopulation | Finanacial restrictions | Clinical reasons | Economic reasons | ||
| MCDA | Positive | Cystadane, Volibris, Torisel, Glivec (DFSP), Glivec (GIST) | Zavesca, Kuvan, Increlex | Ventavis, Tracleer, Nexavar (HCC), Nplate, Tasigna, Glivec (MM), Yondelis | Zavesca, Tasigna, Yondelis | Elaprase, Fabrazyme, Somavert, Torisel | Fabrazyme, Somavert, Torisel, Nexavar (RCC) |
| Negative | Vidaza, Glivec (ALL Ph+), Glivec (MDS/MPD), Revatio | None | Revlimid (MM/S), Sprycel, Atriance) | Revlimid (MM/S), Atriance | None | None | |